# Study of GP681 Tablets Compared With Placebo in Patients With Influenza at High Risk of Influenza Complications

> **NCT06573008** · PHASE3 · RECRUITING · sponsor: **Jiangxi Qingfeng Pharmaceutical Co. Ltd.** · enrollment: 328 (estimated)

## Conditions studied

- Influenza, Human

## Interventions

- **DRUG:** GP681 40mg
- **DRUG:** GP681 Simulant

## Key facts

- **NCT ID:** NCT06573008
- **Lead sponsor:** Jiangxi Qingfeng Pharmaceutical Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-11
- **Primary completion:** 2025-12-30
- **Final completion:** 2025-12-30
- **Target enrollment:** 328 (ESTIMATED)
- **Last updated:** 2024-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06573008

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06573008, "Study of GP681 Tablets Compared With Placebo in Patients With Influenza at High Risk of Influenza Complications". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06573008. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*